Search Within

Wassim Abida

  1. "Department of Medicine"
Formats
  1. Meeting Abstract (73)
  2. Journal Article (69)
  3. Editorial (4)
  4. Research Letter (2)
  5. Review (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (152)
  2. Genitourinary Oncology Service (152)
  3. Solid Tumor Oncology Division (152)
  4. GSK Faculty (71)
  5. Human Oncology and Pathogenesis Program (67)
  6. Sloan Kettering Institute Postdocs (57)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (37)
  3. David Solit (36)
  4. Nikolaus Schultz (32)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (2)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (38)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (42)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (15)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (152)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
    Journal Article

    Brannon, A. R.; Jayakumaran, G.; Diosdado, M.; Patel, J.; Razumova, A.; Hu, Y.; Meng, F.; Haque, M.; Sadowska, J.; Murphy, B. J.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients
    Journal Article

    Tsui, D. W. Y.; Cheng, M. L.; Shady, M.; Yang, J. L.; Stephens, D.; Won, H.; Srinivasan, P.; Huberman, K.; Meng, F.; Jing, X.; more...
    Genome Medicine (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Immunohistochemistry-based assessment of RB1 status in correlation with genomic sequencing and p16 expression in high-risk localized and metastatic castration-resistant prostate cancer
    Meeting Abstract

    Chen, J. F.; Gandhi, J.; Chang, J.; Gupta, S.; Abida, W.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Al-Ahmadie, H.; Fine, S.; more...
    Modern Pathology (2021)

    Fulltext@MSK | Save
  • Immunohistochemistry-based assessment of RB1 status in correlation with genomic sequencing and p16 expression in high-risk localized and metastatic castration-resistant prostate cancer
    Meeting Abstract

    Chen, J. F.; Gandhi, J.; Chang, J.; Gupta, S.; Abida, W.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Al-Ahmadie, H.; Fine, S.; more...
    Laboratory Investigation (2021)

    Fulltext@MSK | Save
  • Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms
    Meeting Abstract

    Tukachinsky, H.; Madison, R.; Chung, J.; Dennis, L.; Fendler, B.; Morley, S.; Zhong, L.; Graf, R.; Ross, J. S.; Alexander, B. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors
    Meeting Abstract

    Abida, W.; Sanay, E.; Lukashchuk, N.; Pierce, A.; de Graaf, W.; Lau, A.; Ros, V. R.; Kurian, N.; Parr, G.; LoembE, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA plus ) metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Patnaik, A.; Campbell, D.; Shapiro, J. D.; Bryce, A. H.; McDermott, R. S.; Sautois, B.; Vogelzang, N. J.; Bambury, R. M.; Voog, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts
    Meeting Abstract

    Dean, E.; Krebs, M. G.; Im, S. A.; Campone, M.; Postel-Vinay, S.; Arkenau, T.; Lopez, J.; Abida, W.; Jodrell, D.; Lee, K. W.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save